CLINICAL_TRIALS
trial_result
· 2022-12-05
Clinical Trial Update: ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis [Phase 2]
Summary
Phase 2 trial update for ISIS 104838, an inhibitor targeting TNF, in active rheumatoid arthritis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED